Wound management test kit Genedrive®

geneticmolecular

Prevention - reduces the likelihood of aminoglycoside induced hearing loss Rapid results - point-of-care genetic test yields results in 30 minutes Simple to use - by healthcare professionals with minimal training An in vitro diagnostic (IVD) molecular assay for use in human buccal cells The Genedrive® MT-RNR1 ID Kit used in conjunction with the Genedrive® System provides an automated result of an individual's MT-RNR1 m.1555 variant status to inform the clinician ahead of antibiotic treatment decisions. ​ The Genedrive® MT-RNR1 ID Kit is intended to be used by healthcare professionals within a near patient setting.​ The Genedrive® System is a compact benchtop system that provides rapid nucleic amplification, detection and result reporting without the need for data interpretation Reduces the likelihood of aminoglycoside induced hearing loss Provides a clear patient benefit by informing the clinician ahead of prescription Rapid genetic screening prior to aminoglycoside treatment Individuals with the MT-RNR1 m.1555A>G variant develop profound irreversible hearing loss if exposed to aminoglycoside - population-based studies estimate prevalence of 1:500 (0.2%) Single use, cost effective test for use by healthcare professionals with minimal training Easy adoption into existing neonatal admissions process to inform clinicians ahead of antibiotic treatment decisions Non-invasive test using buccal swabs from the inner cheek